RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 FREEDOM Trial Analysis: Denosumab Discontinuation and Associated Fracture Incidence
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 9
SP 28
OP 28
DO 10.1177/155989771209022
UL http://mdc.sagepub.com/content/12/9/28.abstract
AB Patients with osteoporosis who discontinue denosumab have transient increases in bone remodeling and decreases in bone mineral density [Miller PD et al. Bone 2008; Bone HG et al. J Clin Endocrinol Metab 2011], but the effect of discontinuation on fracture risk is not clear. The Phase 3 Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months [FREEDOM; NCT00089791] trial determined the incidence of fractures in postmenopausal patients with osteoporosis after stopping denosumab therapy.